During the 14th Five-Year Plan (2021-25), Pudong New Area strengthened its leadership in high-end industry, with the biopharmaceutical sector generating 409.9 billion yuan ($58 billion) in 2024 — about 40 percent of Shanghai.

Nearly 2,000 pipelines are under development, including more than 800 Class I new drugs, about one-fifth of the national total.

Since 2021, Pudong New Area has secured approvals for 23 Class I innovative drugs and 27 domestic Class III innovative medical devices. In 2025, six Class I new drugs received approval, accounting for 14 percent nationwide, while overseas licensing deals made up 31 percent in China and 14 percent globally.

Recently, Professor Chi Hao's cardiothoracic surgery team at Shuguang Hospital conducted three procedures using the JediVision® lung-nodule localization system, demonstrating AI-AR-guided navigation that improves real-time visualization and surgical accuracy.

JediVision® developed by Shanghai Futuo Zhida Medical Tech. [Photo/WeChat ID: pdnews]

Developed by Shanghai Futuo Zhida Medical Technology Co in Pudong New Area, JediVision® integrates AI, augmented reality, and advanced surgical tools. It translates CT-based nodule positions into operative coordinates using proprietary algorithms and projects surgical plans onto the patient while tracking instruments in real time.

Pudong New Area's medical device ecosystem continues to grow, with premium products — from AI-assisted navigation systems to interventional tools — gaining global recognition.

Innovations such as MicroPort®'s Toumai® Remote Surgery System and the Minos® aortic stent-graft are broadening their global impact, underscoring Pudong New Area's role in developing next-generation precision medicine.